Clinical Trial

Low or High Botox Dilution for the Hemiplegic Gait?

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated December 6, 2024 (before its estimated August 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
There is debate regarding the efficiency of different dilutions of Botulin toxin type A (BTX-A) injections. Some authors believe that highly diluted BTX-A injections achieve greater neuromuscular blockade resulting in higher spasticity reduction. On the other hand, other researchers suggest that there is no difference in spasticity decrease if either high or low volume toxin is being injected. Studies on this subject lack either the design or the power of study was low. Therefore, there is no clear guideline for an optimal botulinum toxin dilution protocol. In an attempt to have a better understanding, a cross over study was designed. The material will be patients with spastic hemiparesis which will be treated with Botulin toxin at different dilutions. Gait analysis will be used for the evaluation of the Botulin toxin injection on gait improvement. To the best of our knowledge such a trial hasn't been performed yet.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2020-11-10; most recent amendment 2024-12-04.
Status change: Not Yet Recruiting → Recruiting 2020-12-10
Trial Details
NCT Number NCT04630873
Lead Sponsor University of Ioannina
Conditions Post Stroke Spastic Hemiplegia
Enrollment 20 participants
Start Date 2020-11-20
Primary Completion 2025-08-01 (estimated)
Study Completion 2025-08-01 (estimated)
Updated on ClinicalTrials.gov 2024-12-06